ClinicalTrials.gg
CompletedNCT06035276Updated Jun 26, 2025

Biosensor and Environmental Sensor Development Within the REMEDIA Project

An interventional study of Exposure to clean air and Exposure to urban air in Chronic Obstructive Pulmonary Disease and Healthy, sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine. Completed at 1 site in Germany. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany — 33 open to participants now, 46 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · Germany.

Enrollment
378th of 441
25 · median 156
Started
2023
with 15 others
No phase
108 of 539
8 open now
Registered
495th of 539
by date

Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, this one is the 378th largest by enrollment of the 441 interventional ones that give a count, is one of 16 that started in 2023, is one of 108 with no phase, and was the 495th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

33 of the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, or all of them as a file.
02

Study summary

The aim of this proof-of-concept study is to obtain data that will contribute to the development of sensor devices (biosensor and environmental sensor) for patients with lung diseases (e.g. COPD). The study aims to validate our previous results from healthy subjects by joint testing of the biosensor and environmental device in a real-world setting. Healthy subjects and COPD subjects will be exposed to air of a traffic dense urban region ("urban" air) and to filtered indoor air ("clean" air) during activity and rest. Environmental and biomarker sensors will be used to measure several biomarkers and environmental conditions.

Read the detailed description

The EU-sponsored REMEDIA project (Impact of exposome on the course of lung diseases, Grant agreement ID 874753) contributes to the understanding of the influence of the exposome on chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). While COPD is considered to be mainly related to the external exposome (smoking, ambient particulate matter, household air pollution, occupational particulate matter, ozone and second-hand smoke) CF is the consequence of a genetic defect in the CFTR gene, which gives an essential role to factors outside of the exposome. However, COPD and CF share common characteristics such as high phenotypic variability of unknown origin, and similar progressive loss of lung function with small bronchi alterations. Given this high phenotypic variability it is clear that the overall picture must be supplemented by considering additional components of the exposome. The REMEDIA project investigates the specific exposome associated with particular COPD or CF phenotypes.

Objective of work package 3 within the REMEDIA project is the development of a mobile environmental sensor toolbox that is capable to assess the external exposome (temperature, humidity, particulate matter (PM), volatile organic compounds (VOC), nitrogen dioxide (NO2), ozone (O3), carbon-monoxide (CO), and sulfur dioxide (SO2)) and a mobile biosensor unit that can measure inflammatory biomarkers in exhaled breath. Currently specific sensors for the analysis of hexanal, nitrotyrosine and neutrophils elastase are included into the sensor tool kit. Other relevant molecules are evaluated and selected in other work packages and could be included into the tool kit.

Our previous experimental exposure study focused on the major environmental air pollutant ozone and was supposed to test the biosensor unit under close to "real life conditions". Ozone is known to cause a temporary neutrophilic airway inflammation, which is also typical for patients with COPD and CF.

This proof-of-concept study aims to validate our previous results from healthy subjects by joint testing of the biosensor and environmental device in a real-world setting. Healthy subjects and COPD subjects will be exposed to air of a traffic dense urban region ("urban" air) and to filtered indoor air ("clean" air) during activity and rest. The biosensor will measure the following biomarker: 3-Nitrotyrosin, Hexanal and Neutrophil Elastase. The environmental sensor will measure the following parameters: CO, O3, SO2, NO2, VOC, PM10, PM2.5, temperature, humidity, light and sound level. The collected data will be evaluated in terms of population and exposure.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Healthy
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy subjects:

  1. Able and willing to give written .
  2. Healthy male and female subjects aged 40-70 years, inclusive. Women will be considered for inclusion if they are:

    Not pregnant, as confirmed by pregnancy test (see assessment schedule), and not breastfeeding.

    Of non- (i.e., physiologically incapable of becoming pregnant, including any female who is , with documented proof of hysterectomy or tubal ligation, without an alternative medical cause according to the Clinical Trial Facilitation Group (CTFG) document "Recommendations related to and pregnancy testing in clinical trials").

    Of childbearing potential and using a highly effective method of contraception according to the contraception requirements in section 7.2 from two weeks prior to visit 1 until the end of study participation.

  3. Normal lung function with predicted ≥ 80% and FEV1/FVC≥70%.
  4. of ≥18.6 and ≤30 kg/m2
  5. Non-smoker or former smoker with \<10 pack years who had stopped smoking (including e-cigarettes) for at least 12 months before Screening.

subjects:

  1. Able and willing to give written informed consent.
  2. Male and female subjects aged 40-70 years, inclusive. Women will be considered for inclusion if they are:

    Not pregnant, as confirmed by pregnancy test (see assessment schedule), and not breastfeeding.

    Of non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is postmenopausal, with documented proof of hysterectomy or tubal ligation, without an alternative medical cause according to the Clinical Trial Facilitation Group (CTFG) document "Recommendations related to contraception and pregnancy testing in clinical trials").

    Of childbearing potential and using a highly effective method of contraception according to the contraception requirements in section 7.2 from two weeks prior to visit 1 until the end of study participation.

  3. Clinical diagnosis of COPD stage 1 to 2 (GOLD classification)
  4. FEV1/FVC \<70% post-bronchodilator at visit 1
  5. FEV1 ≥50% of the predicted normal value post-bronchodilator at visit 1
  6. FEV1 ≥1.5L pre-bronchodilator
  7. Ex-smokers for at least 12 months with a history of at least 10 pack years.
  8. Body mass index of ≥ 18.6 and ≤30 kg/m2.

Exclusion criteria

Exclusion criteria:

Healthy subjects:

  1. Past or present disease, which as judged by the investigator, may affect the outcome of the study or put the subject at risk because of participation in the study. These diseases include, but are not limited to, coagulation disorders, cardiovascular disease, , hepatic disease, renal disease, haematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis)
  2. Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for short term pain relief, oral medication, hormonal replacement therapy, dietary and vitamin supplements.
  3. allergy against airborne allergens (such as pollen).
  4. Infections of the lower respiratory tract within 4 weeks prior to screening
  5. Infections of the upper respiratory tract within 2 weeks prior to screening
  6. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, lung function, or at Visit 1, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study.
  7. Positive drug screen for methadone, cannabis, opiates, cocaine metabolites, amphetamines, barbiturates and benzodiazepines at visit 1
  8. History of drug or alcohol abuse
  9. Risk of non-compliance with study procedures
  10. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study

subjects:

  1. Past or present disease other than COPD, which as judged by the investigator, may affect the outcome of the study or put the subject at risk because of participation in the study. These diseases include, but are not limited to, coagulation disorders cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis).
  2. Regular intake of any prescribed or over the counter medication, which as judged by the investigator, may affect the outcome of the study or put the subject at risk because of participation in the study. Explicitly not allowed is treatment with GCS, NSAIDs or any other anti-inflammatory medication. Explicitly allowed is treatment with SABA/LABA/LAMA, paracetamol for pain relief, antihypertensives, lipid-lowering medications, antidiabetics, oral contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements.
  3. Clinically relevant allergy against airborne allergens (such as pollen).
  4. Infections of the lower respiratory tract within 4 weeks prior to screening.
  5. Infections of the upper respiratory tract within 2 weeks prior to screening
  6. Exacerbation of COPD (treatment with oral or parenteral antibiotics and/or oral or parenteral GCS and/or hospitalization related to COPD) within 60 days before visit 1.
  7. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, lung function, or ECG at visit 1, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study.
  8. Positive drug screen for methadone, cannabis, opiates, cocaine metabolites, amphetamines, barbiturates and benzodiazepines at visit 1.
  9. History of drug or alcohol abuse.
  10. Risk of non-compliance with study procedures.
  11. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Other
    Healthy subjects

    Other: Exposure to clean air · Other: Exposure to urban air

  • Other
    COPD patients

    Other: Exposure to clean air · Other: Exposure to urban air

Interventions

  • OtherExposure to clean air

    Subjects will be exposed to filtered indoor air ("clean" air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest.

  • OtherExposure to urban air

    Subjects will be brought to a traffic dense urban region ("urban air") with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the "clean air" regimen.

06

What researchers measure

Primary outcomes

  1. Concentration of Biomarkers in exhaled breath condensate collected by biosensor

    3-Nitrotyrosin

    Time frame: On day 1,3,5,8,10, and 12 of the study

  2. Concentration of Biomarkers in exhaled breath condensate collected by biosensor

    Hexanal

    Time frame: On day 1,3,5,8,10, and 12 of the study

  3. Concentration of Biomarkers in exhaled breath condensate collected by biosensor

    Neutrophil Elastase

    Time frame: On day 1,3,5,8,10, and 12 of the study

  4. Data collected by environmental sensor

    Concentration of CO

    Time frame: Through study completion (study days 1-12)

  5. Data collected by environmental sensor

    Concentration of O3

    Time frame: Through study completion (study days 1-12)

  6. Data collected by environmental sensor

    Concentration of SO2

    Time frame: Through study completion (study days 1-12)

  7. Data collected by environmental sensor

    Concentration of NO2

    Time frame: Through study completion (study days 1-12)

  8. Data collected by environmental sensor

    Concentration of VOC

    Time frame: Through study completion (study days 1-12)

  9. Data collected by environmental sensor

    Concentration of PM10

    Time frame: Through study completion (study days 1-12)

  10. Data collected by environmental sensor

    Concentration of PM2.5

    Time frame: Through study completion (study days 1-12)

  11. Data collected by environmental sensor

    temperature

    Time frame: Through study completion (study days 1-12)

  12. Data collected by environmental sensor

    Humidity of the subject's ambient air within a range of 0 % to 100 % and with a resolution of 1 %

    Time frame: Through study completion (study days 1-12)

  13. Data collected by environmental sensor

    Light level of the subject's environment within a range of 350 nm to 1100 nm

    Time frame: Through study completion (study days 1-12)

  14. Data collected by environmental sensor

    Sound level of the subject's environment within a range of 20 Hz to 10 kHz and with a resolution of 1 Pa / 1 kHz

    Time frame: Through study completion (study days 1-12)

07

Study locations

1 site
  • Fraunhofer ITEM
    Hanover, Lower Saxony 30625, Germany
08

References and documents

Publications

  • Fernandez Fernandez E, De Santi C, De Rose V, Greene CM. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 Jun;12(6):483-492. doi: 10.1080/17476348.2018.1475235. Epub 2018 May 23. PubMed 29750581 ↗
  • De Rose V, Molloy K, Gohy S, Pilette C, Greene CM. Airway Epithelium Dysfunction in Cystic Fibrosis and COPD. Mediators Inflamm. 2018 Apr 8;2018:1309746. doi: 10.1155/2018/1309746. eCollection 2018. PubMed 29849481 ↗
  • Holz O, Jorres RA, Timm P, Mucke M, Richter K, Koschyk S, Magnussen H. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med. 1999 Mar;159(3):776-84. doi: 10.1164/ajrccm.159.3.9806098. PubMed 10051250 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2024, 7 months.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 7 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 13, 2023
StartActual
Aug 28, 2023
Primary completionActual
Apr 19, 2024
CompletionActual
Apr 1, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06035276
Lead sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Aug 28, 2023
Primary completion
Apr 19, 2024
Completion
Apr 1, 2025
Last update
Jun 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion